EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles

Huei-Chun Liu, Ming-Jang Chiu, Chin-Hsien Lin, Shieh-Yueh Yang

Dementia and Geriatric Cognitive Disorders Extra · 2020-03-26 · 10 (1) · 46-55

DOI: 10.1159/000506278 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Blood biomarkers of Alzheimer’s disease (AD) have attracted much attention of researchers in recent years. In clinical studies, repeated freeze/thaw cycles often occur and may influence the stability of biomarkers. This study aims to investigate the stability of amyloid-β 1–40 (Aβ1–40), amyloid-β 1–42 (Aβ1–42), and total tau protein (T-tau) in plasma over freeze/thaw cycles. Methods: Plasma samples from healthy controls (n = 2), AD patients (AD, n =3) and Parkinson’s disease patients (PD, n = 3) were collected by standardized procedure and immediately frozen at –80°C. Samples underwent 5 freeze/thaw (–80°C/room temperature) cycles. The concentrations of Aβ1–40, Aβ1–42, and T-tau were monitored during the freeze/thaw tests using an immunomagnetic reduction (IMR) assay. The relative percentage of concentrations after every freeze/thaw cycle was calculated for each biomarker. Results: A tendency of decrease in the averaged relative percentages over samples through the freeze and thaw cycles for Aβ1–40 (100 to 97.11%), Aβ1–42 (100 to 94.99%), and T-tau (100 to 95.65%) was found. However, the decreases were less than 6%. For all three biomarkers, no statistical significance was found between the levels of fresh plasma and those of the plasma experiencing 5 freeze/thaw cycles (p > 0.1). Conclusions: Plasma Aβ1–40, Aβ1–42, and T-tau are stable through 5 freeze/thaw cycles measured with IMR.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →